OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Neuromuscular Diseases is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Gene Therapy for Duchenne Muscular Dystrophy	67
Molecular Mechanisms of Skeletal Muscle Hypertrophy	64
Prospective Cohort Study of Nusinersen Treatment in Adults with Spinal Muscular Atrophy	50
Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial	47
Safety Monitoring of Gene Therapy for Spinal Muscular Atrophy with Onasemnogene Abeparvovec –A Single Centre Experience	38
Measuring Outcomes in Adults with Spinal Muscular Atrophy – Challenges and Future Directions – Meeting Report	38
COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome	34
Exon-Skipping in Duchenne Muscular Dystrophy	34
Mechanisms and Clinical Applications of Glucocorticoid Steroids in Muscular Dystrophy	34
Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy	32
Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada	27
Feeding and Swallowing Problems in Infants with Spinal Muscular Atrophy Type 1: an Observational Study	25
Current View of Diagnosing Small Fiber Neuropathy	25
Beyond the Traditional Clinical Trials for Amyotrophic Lateral Sclerosis and The Future Impact of Gene Therapy	25
Correlation Between Quantitative MRI and Muscle Histopathology in Muscle Biopsies from Healthy Controls and Patients with IBM, FSHD and OPMD	25
Stride Velocity 95th Centile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials	25
A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment	24
Comparison of Long-term Ambulatory Function in Patients with Duchenne Muscular Dystrophy Treated with Eteplirsen and Matched Natural History Controls	22
Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience	22
Adult North Star Network (ANSN): Consensus Guideline For The Standard Of Care Of Adults With Duchenne Muscular Dystrophy	20